SETH LERNER to Female
This is a "connection" page, showing publications SETH LERNER has written about Female.
Connection Strength
0.751
-
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022 Apr; 207(4):779-788.
Score: 0.023
-
Re: Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. 2022 01; 81(1):118-119.
Score: 0.023
-
Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer. Urol Oncol. 2021 07; 39(7):434.e23-434.e29.
Score: 0.022
-
Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma. Cancer Chemother Pharmacol. 2021 06; 87(6):799-805.
Score: 0.022
-
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
Score: 0.021
-
Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-na?ve High-grade Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018 07; 4(4):522-524.
Score: 0.019
-
Molecular Landscape of Non-Muscle Invasive Bladder Cancer. Cancer Cell. 2017 11 13; 32(5):550-551.
Score: 0.018
-
Editorial Comment. J Urol. 2016 Jan; 195(1):59.
Score: 0.015
-
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun; 111(7):923-8.
Score: 0.015
-
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
Score: 0.015
-
Targeted therapies for metastatic bladder cancer. J Urol. 2015 Jan; 193(1):8-9.
Score: 0.014
-
Bladder cancer: Always consider extravesical sites when BCG fails. Nat Rev Urol. 2014 Jan; 11(1):11-2.
Score: 0.013
-
Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int. 2012 Sep; 110(5):630-6.
Score: 0.012
-
Variables affecting long-term maintenance of renal function following ileal based urinary diversion. Eur Urol. 2012 Mar; 61(3):498-500; discussion 500-2.
Score: 0.012
-
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9.
Score: 0.011
-
Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012 May-Jun; 30(3):285-9.
Score: 0.011
-
Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology. 2008 Jul; 72(1):133-7.
Score: 0.009
-
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009 Mar-Apr; 27(2):155-9.
Score: 0.009
-
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol. 2007 May; 177(5):1727-31.
Score: 0.009
-
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422.
Score: 0.008
-
Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006 Nov 15; 12(22):6663-76.
Score: 0.008
-
Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2.
Score: 0.008
-
Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006 Dec; 50(6):1254-60; discussion 1261-2.
Score: 0.008
-
Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology. 2005 Aug; 66(2):441-6.
Score: 0.008
-
Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder. J Clin Oncol. 2005 Jul 01; 23(19):4458-9.
Score: 0.007
-
Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol. 2005 Jul; 48(1):69-76.
Score: 0.007
-
Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol. 2004 May; 171(5):1830-4.
Score: 0.007
-
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004 Mar 15; 22(6):1014-24.
Score: 0.007
-
Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):626-30.
Score: 0.007
-
The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol. 2003 Dec; 170(6 Pt 1):2244-7.
Score: 0.007
-
Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003 Dec; 170(6 Pt 1):2248-52.
Score: 0.007
-
Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol. 2003 Sep; 170(3):985-9.
Score: 0.007
-
Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003 Jun; 61(6):1140-5.
Score: 0.006
-
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
Score: 0.006
-
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer. 2002 Dec 15; 95(12):2494-9.
Score: 0.006
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
Score: 0.006
-
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
Score: 0.006
-
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441.
Score: 0.006
-
Rebuilding the lower urinary tract after cystectomy: a roadmap for patient selection and counseling. Semin Urol Oncol. 2001 Feb; 19(1):24-36.
Score: 0.006
-
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
Score: 0.005
-
Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001 Jan-Feb; 21(1B):575-8.
Score: 0.005
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
Score: 0.005
-
Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
Score: 0.005
-
In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. Mol Ther. 2000 Sep; 2(3):211-7.
Score: 0.005
-
Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res. 2000 May-Jun; 20(3A):1359-65.
Score: 0.005
-
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891.
Score: 0.005
-
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020 04; 77(4):420-433.
Score: 0.005
-
Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
Score: 0.005
-
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 07 05; 10(1):2977.
Score: 0.005
-
Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur Urol. 2019 08; 76(2):200-206.
Score: 0.005
-
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888.
Score: 0.005
-
Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr. 2018 02 01; 107(2):208-216.
Score: 0.004
-
Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer. 2018 05 01; 142(9):1797-1804.
Score: 0.004
-
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prev Res (Phila). 2017 Oct; 10(10):588-597.
Score: 0.004
-
Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
Score: 0.004
-
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017 10; 72(4):641-649.
Score: 0.004
-
Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. Eur Urol Focus. 2018 12; 4(6):907-915.
Score: 0.004
-
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 10; 72(4):544-554.
Score: 0.004
-
Conservative management of spontaneous rupture of Kock orthotopic ileal reservoir. Urology. 1997 Apr; 49(4):629-31.
Score: 0.004
-
Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
Score: 0.004
-
Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017 Mar 01; 123(5):794-801.
Score: 0.004
-
Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 02; 3(1):130-135.
Score: 0.004
-
Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol. 2016 06; 27(6):1100-1106.
Score: 0.004
-
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan; 34(1):4.e11-7.
Score: 0.004
-
External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. J Urol. 2016 Feb; 195(2):283-9.
Score: 0.004
-
The role of surgery in the management of pediatric pelvic rhabdomyosarcoma. J Urol. 1995 Aug; 154(2 Pt 1):540-5.
Score: 0.004
-
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015 Jan 08; 517(7533):209-13.
Score: 0.004
-
Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programs. J Cancer Educ. 2014 Dec; 29(4):739-45.
Score: 0.004
-
Renal cell carcinoma extending into the retrohepatic inferior vena cava. Tex Heart Inst J. 2014 Dec; 41(6):671-2.
Score: 0.004
-
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33.
Score: 0.004
-
The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3377-82.
Score: 0.003
-
The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3383-9.
Score: 0.003
-
Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 2014 Apr; 83(4):863-7.
Score: 0.003
-
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014 Apr 15; 120(8):1272-80.
Score: 0.003
-
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int. 2014 Jan; 113(1):11-23.
Score: 0.003
-
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu?rin. J Urol. 2013 Oct; 190(4):1200-4.
Score: 0.003
-
The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993 Apr; 149(4):758-64; discussion 764-5.
Score: 0.003
-
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013 Jun; 11(2):175-81.
Score: 0.003
-
Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013 Jun; 111(8):1215-21.
Score: 0.003
-
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec; 188(6):2391-7.
Score: 0.003
-
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57.
Score: 0.003
-
Racial/ethnic differences in upper-tract urothelial cancer. Ethn Dis. 2012; 22(3):295-301.
Score: 0.003
-
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
Score: 0.003
-
A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. Urol Oncol. 2013 Feb; 31(2):234-40.
Score: 0.003
-
Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6.
Score: 0.003
-
Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011 Apr; 185(4):1216-21.
Score: 0.003
-
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61.
Score: 0.003
-
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int. 2011 Sep; 108(5):687-92.
Score: 0.003
-
Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol. 2010 Sep; 184(3):888-94.
Score: 0.003
-
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
Score: 0.003
-
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010 Jun; 183(6):2165-70.
Score: 0.003
-
A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? Eur Urol. 2010 Sep; 58(3):374-83.
Score: 0.003
-
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther. 2010 May; 9(5):1128-35.
Score: 0.003
-
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol. 2010 May; 183(5):1757-63.
Score: 0.003
-
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010 Jun; 56(6):e1-48.
Score: 0.003
-
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May; 105(10):1402-12.
Score: 0.003
-
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010 Jan; 183(1):68-75.
Score: 0.003
-
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010 Jan; 183(1):87-93.
Score: 0.003
-
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9.
Score: 0.003
-
p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010 Feb; 105(4):489-95.
Score: 0.002
-
p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009 Sep; 182(3):907-13.
Score: 0.002
-
Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol. 2009 Aug; 182(2):459-65; discussion 465.
Score: 0.002
-
Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther. 2009 Jul; 8(7):1772-8.
Score: 0.002
-
Outcome of combined liver and kidney transplantation in hepatitis C: a single-center long-term follow-up experience. Transplant Proc. 2009 Jun; 41(5):1713-6.
Score: 0.002
-
Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009 May; 103(10):1359-62.
Score: 0.002
-
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int. 2008 Jun; 101(11):1356-61.
Score: 0.002
-
Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol. 2008 Jul; 180(1):116-20.
Score: 0.002
-
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology. 2008 Feb; 71(2):302-7.
Score: 0.002
-
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008 Jan 15; 112(2):315-25.
Score: 0.002
-
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
Score: 0.002
-
Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU Int. 2008 Feb; 101(4):450-4.
Score: 0.002
-
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int. 2007 Nov; 100(5):1015-20.
Score: 0.002
-
Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology. 2007 Jun; 69(6):1221-6.
Score: 0.002
-
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
Score: 0.002
-
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007 Mar; 51(3):699-706; discussion 706-8.
Score: 0.002
-
Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology. 2006 Sep; 68(3):538-42.
Score: 0.002
-
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007 Jan; 51(1):152-60.
Score: 0.002
-
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007 Jan; 51(1):137-49; discussion 149-51.
Score: 0.002
-
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006 Jun; 175(6):2048-53; discussion 2053.
Score: 0.002
-
Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol. 2006 May; 175(5):1645-9; discussion 1649.
Score: 0.002
-
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar; 78(3):464-79.
Score: 0.002
-
Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005 Oct; 19(10):1788-93.
Score: 0.002
-
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005 Sep 20; 23(27):6533-9.
Score: 0.002
-
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20; 23(24):5746-56.
Score: 0.002
-
Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol. 2005 Apr; 29(4):443-51.
Score: 0.002
-
Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):878-84.
Score: 0.002
-
Case-control analysis of dietary folate and risk of bladder cancer. Nutr Cancer. 2005; 53(2):144-51.
Score: 0.002
-
Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr. 2004 Dec; 134(12):3362-9.
Score: 0.002
-
Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol. 2004 May; 171(5):1823-8; discussion 1827-8.
Score: 0.002
-
Field testing the influence of sperm competition based on sperm mobility in breeder turkey toms. Br Poult Sci. 2003 Jul; 44(3):498-504.
Score: 0.002
-
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003 May; 61(5):1053-8.
Score: 0.002
-
Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol. 2003 Feb; 169(2):714-7.
Score: 0.002
-
Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
Score: 0.002
-
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Sep; 43(9):1755-62.
Score: 0.002
-
Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15; 92(12):2985-92.
Score: 0.001
-
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001 Jul 01; 98(1):181-6.
Score: 0.001
-
Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001 May; 12(5):621-5.
Score: 0.001
-
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001 Apr 18; 93(8):597-604.
Score: 0.001
-
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15; 19(8):2165-70.
Score: 0.001
-
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001 Apr; 7(4):795-9.
Score: 0.001
-
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 01; 19(5):1414-20.
Score: 0.001
-
Giant bilateral renal angiomyolipomas associated with tuberous sclerosis. Urology. 2001 Mar; 57(3):554.
Score: 0.001
-
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001 Jan 01; 97(1):256-63.
Score: 0.001
-
Predictors of survival after In vivo split liver transplantation: analysis of 110 consecutive patients. Ann Surg. 2000 Sep; 232(3):312-23.
Score: 0.001
-
Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res. 2000 Jun; 24(6):469-74.
Score: 0.001
-
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2000 Mar; 37(1-2):71-85.
Score: 0.001
-
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15; 92(4):1165-71.
Score: 0.001
-
Role of splenectomy in chronic lymphocytic leukemia. J Am Coll Surg. 1997 Sep; 185(3):237-43.
Score: 0.001
-
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73.
Score: 0.001
-
Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 1996 Jul; 48(1):28-32.
Score: 0.001
-
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep; 9(9):1444-9.
Score: 0.001
-
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood. 1995 Aug 15; 86(4):1298-300.
Score: 0.001
-
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Jun; 9(6):943-5.
Score: 0.001
-
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993 Sep 15; 82(6):1695-700.
Score: 0.001
-
Unilateral ovariectomy increases loss of primordial follicles and is associated with increased metestrous concentration of follicle-stimulating hormone in old rats. Biol Reprod. 1992 Aug; 47(2):162-8.
Score: 0.001
-
Treatment of staghorn calculi with extracorporeal shock-wave lithotripsy and percutaneous nephrolithotomy. Urology. 1991 Aug; 38(2):145-51.
Score: 0.001